TY - JOUR
T1 - A cardiotonic steroid bufalin-induced differentiation of THP-1 cells. Involvement of Na+, K+-ATPase inhibition in the early changes in proto-oncogene expression
AU - Numazawa, Satoshi
AU - Inoue, Naonori
AU - Nakura, Hironori
AU - Sugiyama, Tadashi
AU - Fujino, Emi
AU - Shinoki, Masa Aki
AU - Yoshida, Takemi
AU - Kuroiwa, Yukio
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1996/7/26
Y1 - 1996/7/26
N2 - Human monocytic leukemia THP-1 cells were induced to differentiate into macrophage-like cells by treatment with cardiotonic steroid bufalin, which was previously shown to interact with the Na+, K+-ATPase with similar kinetics to ouabain, a specific inhibitor of the enzyme. This induction of differentiation was characterized by loss of proliferation, cell adherence, increased ability to reduce Nitro Blue tetrazolium (NBT), and increased expression of interleukin 1β (IL-1β). During this process, bufalin down-regulated c-myb and c-myc expressions and induced c-fos and Egr-1 transcripts. Ouabain also caused similar changes in protooncogene expression and induced phenotypic markers of differentiated cells at concentrations comparable to bufalin. The 12-O-tetradecanoyl phorbol-13-acetate resistant THP-1 cell variant, which was unresponsive to this agent as to growth inhibition and proto-oncogene expression, responded to bufalin. The finding that protein kinase inhibitor H7 failed to inhibit bufalin-mediated c-fos induction further supports the theory that the signal transduction machinery caused by bufalin is separable from the phorbol ester. The cytotoxic effect of high doses of bufalin apparently disappeared in the medium where Na+ was replaced with choline ions. Furthermore, bufalin failed to induce c-fos expression and to downregulate c-myb transcripts in the low-Na+ medium. These findings indicate that an increased intracellular Na+ concentration resulting from the Na+, K+-ATPase inhibition possibly triggers the change in proto-oncogene expression evoked by bufalin.
AB - Human monocytic leukemia THP-1 cells were induced to differentiate into macrophage-like cells by treatment with cardiotonic steroid bufalin, which was previously shown to interact with the Na+, K+-ATPase with similar kinetics to ouabain, a specific inhibitor of the enzyme. This induction of differentiation was characterized by loss of proliferation, cell adherence, increased ability to reduce Nitro Blue tetrazolium (NBT), and increased expression of interleukin 1β (IL-1β). During this process, bufalin down-regulated c-myb and c-myc expressions and induced c-fos and Egr-1 transcripts. Ouabain also caused similar changes in protooncogene expression and induced phenotypic markers of differentiated cells at concentrations comparable to bufalin. The 12-O-tetradecanoyl phorbol-13-acetate resistant THP-1 cell variant, which was unresponsive to this agent as to growth inhibition and proto-oncogene expression, responded to bufalin. The finding that protein kinase inhibitor H7 failed to inhibit bufalin-mediated c-fos induction further supports the theory that the signal transduction machinery caused by bufalin is separable from the phorbol ester. The cytotoxic effect of high doses of bufalin apparently disappeared in the medium where Na+ was replaced with choline ions. Furthermore, bufalin failed to induce c-fos expression and to downregulate c-myb transcripts in the low-Na+ medium. These findings indicate that an increased intracellular Na+ concentration resulting from the Na+, K+-ATPase inhibition possibly triggers the change in proto-oncogene expression evoked by bufalin.
KW - Na, K-ATPase
KW - THP-1
KW - TPA resistance
KW - bufalin
KW - cell differentiation
KW - proto-oncogenes
UR - http://www.scopus.com/inward/record.url?scp=0030602886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030602886&partnerID=8YFLogxK
U2 - 10.1016/0006-2952(96)00210-9
DO - 10.1016/0006-2952(96)00210-9
M3 - Article
C2 - 8694857
AN - SCOPUS:0030602886
SN - 0006-2952
VL - 52
SP - 321
EP - 329
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 2
ER -